INDOUS

Indo Us Biotech Limited

Source: NSE · Updated 4 Nov, 06:28 pm IST

Filed 30 Oct, 04:20 pm IST Q2 FY27 (Sep ’26)Standalone (no consolidated filing)₹ lakhs

Revenue

1,504.63

▼ 51.2% vs Q2 FY26

Operating profit (EBITDA, derived from filing)

-260.07

vs Q2 FY26: n/a

Net profit

-367.14

vs Q2 FY26: n/a

EPS (₹)

-1.83

vs Q2 FY26: n/a

Operating margin

-17.3%

−3080 bps vs Q2 FY26

Net margin

-24.4%

−3560 bps vs Q2 FY26

Swung to loss vs Q2 FY26

Revenue−51% vs Q2 FY26 · −54% vs Q1 FY27

ProfitSwung to loss vs Q2 FY26 · Swung to loss vs Q1 FY27

View official filing ↗

Numbers from the company's structured XBRL filing on NSE, cross-checked with P&L totals.

Previous-quarter and year-ago figures: as originally reported in those quarters' NSE filings; filing PDF not available to confirm restatements.

Quarter comparison

Item	Q2 FY27 (Sep ’26)	Q1 FY27 (Jun ’26)	vs Q1 FY27	Q2 FY26 (Sep ’25)	vs Q2 FY26
Revenue from operations	1,504.63	3,298.68	▼ 54.4%	3,084.65	▼ 51.2%
Other income	4.89	12.37	▼ 60.5%	2.62	▲ 86.6%
Total income	1,509.52	3,311.05	▼ 54.4%	3,087.27	▼ 51.1%
Total expenses	1,874.27	3,003.35	▼ 37.6%	2,731.38	▼ 31.4%
Operating profit (EBITDA)*	-260.07	396.15	—	416.31	—
Profit before tax	-364.75	307.7	—	355.89	—
Tax expense	2.39	3.96	▼ 39.6%	10.68	▼ 77.6%
Net profit	-367.14	303.74	—	345.21	—
EPS (₹)	-1.83	1.51	—	1.72	—
Operating margin	-17.3%	12.0%	−2930 bps	13.5%	−3080 bps
Net margin	-24.4%	9.2%	−3360 bps	11.2%	−3560 bps

Showing Q2 FY27 (Sep ’26) and change vs Q2 FY26. Turn your phone sideways for Q1 FY27 (Jun ’26).

Figures in ₹ lakhs except EPS. Standalone figures from the company's XBRL filing on NSE. Each row is shown only if it reconciles with the others (e.g. PBT − tax = net profit); rows we couldn't verify are left out. Net margin = net profit ÷ revenue. *Operating profit (EBITDA), derived from the filing: profit before exceptional items and tax + finance costs + depreciation − other income. Operating margin = EBITDA ÷ revenue.

All Indo Us Biotech results, dividends & filings ›

Other results filed 30 Oct

POLICYBZR PB Fintech Limited›GMRP&UI GMR Power and Urban Infra Limited›IOLCP IOL Chemicals and Pharmaceuticals Limited›SHAREINDIA Share India Securities Limited›FINPIPE Finolex Industries Limited›LCCPROJECT LCC Projects Limited›TI Tilaknagar Industries Limited›IRMENERGY IRM Energy Limited›QUESS Quess Corp Limited›RELIANCE Reliance Industries Limited›ZEEL Zee Entertainment Enterprises Limited›CHEMBOND Chembond Material Technologies Limited›

Today's results ›

INDO US BIOTECH Q2 FY27 ; NET LOSS OF ₹3.67 CR VS PROFIT ₹3.45 CR (YOY), PROFIT ₹3.04 CR (QOQ)

REVENUE DOWN 51% AT ₹15 CR (YOY), DOWN 54% (QOQ)

EBITDA LOSS OF ₹2.60 CR VS EBITDA ₹4.16 CR (YOY), EBITDA ₹3.96 CR (QOQ)

MARGINS AT -17.3% VS 13.5% (YOY), 12.0% (QOQ)

https://resultkal.com/r/indous-2026-10-30
Source: NSE filing · not investment advice

FAQ

When did Indo Us Biotech announce Q2 FY27 results?

Indo Us Biotech filed its results on NSE on 30 Oct, 04:20 pm IST.

What does QoQ and YoY mean?

QoQ compares with the previous quarter; YoY compares with the same quarter last year. Growth is calculated from the figures in the filing.

Are these Indo Us Biotech figures official?

They are auto-read from the company's NSE filing and may contain errors. Always confirm with the official PDF linked on this page.

Explore

Today's results Results this week Q2 FY27 results dates Dividend stocks this week Bonus issue 2026 Stock split 2026

Figures are auto-read from the company's NSE filing and may contain errors. Check the official filing before deciding. Not investment advice.

← INDOUS overview